Letters and Correspondence

Letters and correspondence submitted for possible publication must be identified as such. Text length must not exceed 500 words and five bibliographic references. A single concise figure or table may be included if it is essential to support the communication. Letters not typed double-spaced will not be considered for publication. Letters not meeting these specifications will not be returned to authors. Letters to the Editor are utilized to communicate a single novel observation or finding. Correspondence is to be used to supplement or constructively comment on the contents of a publication in the journal and cannot exceed the restrictions for Letters to the Editor. The Editor reserves the right to shorten text, delete objectional comments, and make other changes to comply with the style of the journal. Permission for publication must be appended as a postscript. Submissions must be sent to Jay Umbreit, MD, PhD, Editor of Brief Reports/Letters to Editors, American Journal of Hematology, Winship Cancer Institute, Emory University, 1365-B Clifton Road, Suite B4100, Atlanta, GA 30322 to permit rapid consideration for publication.

[1]  Daniel S. Holland,et al.  A review of 76 patients with myelodysplastic syndromes treated with danazol , 1994, Cancer.

[2]  L. Schwartz,et al.  Gemcitabine‐related radiation recall preferentially involves internal tissue and organs , 2004, Cancer.

[3]  D. Karcher,et al.  The bone marrow in human immunodeficiency virus (HIV)-related disease. Morphology and clinical correlation. , 1991, American journal of clinical pathology.

[4]  A. Brandes,et al.  Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine--a report of three cases. , 2000, Anti-cancer drugs.

[5]  A. Avilés,et al.  Randomized study of danazol vs. placebo in myelodysplastic syndromes. , 1989, Archivos de investigacion medica.

[6]  D. Fleming,et al.  Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. , 2000, Blood.

[7]  M. Qazilbash,et al.  Rituximab‐induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia , 2005, American journal of hematology.

[8]  V. Ribrag,et al.  Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. , 2001, The New England journal of medicine.

[9]  R. Camidge,et al.  Characterizing the phenomenon of radiation recall dermatitis. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  S. Savaşan,et al.  Liposomal Amphotericin B as Antifungal Prophylaxis in Bone Marrow Transplant Patients , 2006 .

[11]  M. Markman,et al.  Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. , 2003, Gynecologic oncology.